Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events. We randomly assigned 15,603 patients ...

Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation have high rates of major vascular events. We evaluated the efficacy and safety of the antiplatelet ...

Baseline clinical characteristics were well balanced between the 2 groups (Table 1), and both groups received similar treatments following baseline angiography (Table 2). Although nonsignificant, ...

A comprehensive analysis of nearly 29,000 patients with coronary artery disease (CAD) suggests that clopidogrel, a commonly prescribed blood thinner, is more effective than aspirin in preventing ...

Sept 3 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up ...

The advent of thrombolytic therapy initiated the era of pharmacologic reperfusion in the acute phase of myocardial infarction (MI). Although it was a major improvement in the treatment of acute MI ...

In patients who develop a hypersensitivity reaction to clopidogrel soon after stenting, a short course of oral corticosteroids usually allows them to continue the antiplatelet therapy without ...

Researchers at 37 sites in South Korea have found patients taking clopidogrel after percutaneous coronary intervention (PCI) experienced lower rates of both thrombotic and bleeding events than those ...

The antiplatelet drug clopidogrel helps prevent stent-associated thrombosis, but the antiplatelet effects are quite variable and the clinical consequences can be serious. New findings show that the ...

Clopidogrel is prescribed to help prevent cardiovascular events such as heart attack and stroke in certain adults. It’s a generic medication that's available as the brand-name drug Plavix. The drug ...

A research team has demonstrated that clopidogrel is more effective than aspirin as a long-term antiplatelet therapy in patients at high risk of recurrent cardiovascular events after coronary stent ...

ESTERO, FL / ACCESS Newswire / January 27, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug ...